Protein dose-sparing effect of AS01B adjuvant in a randomized preventive HIV vaccine trial of ALVAC-HIV (vCP2438) and adjuvanted bivalent subtype C gp120.

Zvavahera Mike ChirenjeFatima LaherOne DintweMonde MuyoyetaAllan C deCampZonglin HeNicole GrunenbergFaatima Laher OmarKelly E SeatonLaura PolakowskiAmanda S Woodward DavisLucas MagangaLindsey R BadenKenneth MayerSpyros KalamsMichael KeeferSrilatha EdupugantiBenigno RodriguezIan FrankHyman ScottLynda Stranix-ChibandaSanjay GurunathanMarguerite KoutsoukosOlivier Van Der MeerenCarlos A DiazGranadosCarmen PaezErica Andersen-NissenJames G KublinLawrence CoreyGuido FerrariGeorgia TomarasM Juliana McElrathnull null

Published in: The Journal of infectious diseases (2023)

The 40μg dose gp120/AS01B regimen elicited the highest CD4+ T-cell and binding antibody responses.

Keyphrases

antiretroviral therapy
hiv positive
hiv infected
hiv testing
human immunodeficiency virus
hepatitis c virus
hiv aids
men who have sex with men
early stage
clinical trial
study protocol
binding protein
phase iii
south africa
phase ii
randomized controlled trial
protein protein
small molecule
transcription factor